entacapone vs Trigel
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Parkinson's Disease
Shared mechanism: COMT · full Parkinson's Disease pipeline
entacapone · Comtess
Marketed by Orion Corporation and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: February 2027 · NCT04246437 (registry estimate)
No aligned efficacy figure on record for this race.
Trigel · Lecigon
Marketed by STADA Arzneimittel and partners
NCT02448914 · Phase 1 · completed
This trial had randomized treatment order and an active comparator, and it reached a statistically significant result for its primary measure, but it was not blinded, enrolled only 11 patients, and measured drug blood levels rather than a clinical symptom or functional outcome, so it demonstrates pharmacokinetic exposure rather than a proven clinical benefit.
Next expected readout: September 2030 · NCT07151378 (registry estimate)
Reported efficacy
Dose Adjusted Area Under the Curve (AUC) (0-14h) for Levodopa (During 14 h infusion on 2 consecutive days): Dose Adjusted Area Under the Curve (AUC) (0-14h) for Levodopa (During 14 h infusion on 2 consecutive days): TRIGEL 40.6 h*ng/mL/mg (range 22.3 to 69.4) | Duodopa 29.4 h*ng/mL/mg (range 21.7 to 52.8) (met)
Result source: NCT02448914
Results for Parkinson's Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
These assets measured different things. Their trials share no endpoint in common, so no efficacy row can be built. That is a property of the programmes rather than a gap in the record: each asset's own reported endpoints are listed below.
| Key endpoint | entacapone | Trigel |
|---|---|---|
| OFF time, change | —Not posted · NCT00134966 | —Trial running · NCT07151378 |
| ON time without troublesome dyskinesia, change | —Not posted · NCT00134966 | —Trial running · NCT07151378 |
| UPDRS Part III, change | -3.7 vs -1.8vs Carbidopa/LevodopaNCT002192843 other results
| —Trial running · NCT07151378 |
| MDS-UPDRS Part II, change | —Not posted · NCT00134966 | —Trial running · NCT07151378 |
OFF time, change
- entacapone
- —Not posted · NCT00134966
- Trigel
- —Trial running · NCT07151378
ON time without troublesome dyskinesia, change
- entacapone
- —Not posted · NCT00134966
- Trigel
- —Trial running · NCT07151378
UPDRS Part III, change
- entacapone
- -3.7 vs -1.8vs Carbidopa/LevodopaNCT00219284
3 other results
- -3.6 vs -3.7 NCT00219284
- -3.6 vs -3.3 NCT00219284
- -4 vs -1.4 NCT00391898
- Trigel
- —Trial running · NCT07151378
MDS-UPDRS Part II, change
- entacapone
- —Not posted · NCT00134966
- Trigel
- —Trial running · NCT07151378
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. entacapone: 4 of 4 rows · Trigel: 2 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | entacapone | Trigel |
|---|---|---|
| Dropout rate | 24.4%a NCT00219284 · Phase 4 · registry result, not featured evidence show 2 more results23.9% NCT00391898 · Phase 4 · registry result, not featured evidence — NCT01883505 · Phase 2 · registry result, not featured evidence · combination | — NCT02448914 · Phase 1 · combination · Parkinson's Disease · phase 1 |
| Discontinued due to AEs | 14.4%a NCT00219284 · Phase 4 · registry result, not featured evidence show 2 more results6.5% NCT00391898 · Phase 4 · registry result, not featured evidence — NCT01883505 · Phase 2 · registry result, not featured evidence · combination | — NCT02448914 · Phase 1 · combination · Parkinson's Disease · phase 1 |
| Serious AEs | 4.4%a NCT00219284 · Phase 4 · registry result, not featured evidence show 2 more results2.2% NCT00391898 · Phase 4 · registry result, not featured evidence 0% NCT01883505 · Phase 2 · registry result, not featured evidence · combination | 0% NCT02448914 · Phase 1 · combination · Parkinson's Disease · phase 1 |
| Most frequent reported AEs | a nausea 17.2% diarrhoea 16.1% dizziness 8.9% NCT00219284 · Phase 4 · registry result, not featured evidence show 2 more resultsdyskinesia 15.6% anxiety 11.1% retching 6.7% NCT00391898 · Phase 4 · registry result, not featured evidence back pain 12.5% (placebo 0%) pain in extremity 12.5% (placebo 9.1%) abdominal pain lower 0% (placebo 0%) NCT01883505 · Phase 2 · registry result, not featured evidence · combination | headache 27.3% dizziness 18.2% injection site haematoma 9.1% NCT02448914 · Phase 1 · combination · Parkinson's Disease · phase 1 |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
entacapone
show 3 more results
show 2 more results
show 3 more results
Trigel
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: entacapone's landscape · Trigel's landscape